News coverage about Apricus Biosciences (NASDAQ:APRI) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apricus Biosciences earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3045468019874 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several brokerages recently commented on APRI. Zacks Investment Research downgraded shares of Apricus Biosciences from a “buy” rating to a “sell” rating in a research report on Tuesday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $4.50 price objective on shares of Apricus Biosciences in a research note on Tuesday, September 5th.
Shares of Apricus Biosciences (APRI) traded down $0.03 on Friday, hitting $1.84. 220,606 shares of the stock traded hands, compared to its average volume of 186,692. Apricus Biosciences has a 52 week low of $0.86 and a 52 week high of $4.07. The firm has a market cap of $28.45, a price-to-earnings ratio of 3.17 and a beta of 0.44.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Apricus Biosciences (APRI) Share Price” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://weekherald.com/2017/12/30/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-apricus-biosciences-apri-share-price.html.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.